1125 related articles for article (PubMed ID: 12814430)
21. CDK inhibitors: from the bench to clinical trials.
Rizzolio F; Tuccinardi T; Caligiuri I; Lucchetti C; Giordano A
Curr Drug Targets; 2010 Mar; 11(3):279-90. PubMed ID: 20210753
[TBL] [Abstract][Full Text] [Related]
22. [The serine/threonine kinases that control cell cycle progression as therapeutic targets].
Diallo A; Prigent C
Bull Cancer; 2011 Nov; 98(11):1335-45. PubMed ID: 22020767
[TBL] [Abstract][Full Text] [Related]
23. Cyclin-dependent kinases as targets for cancer therapy.
Senderowicz AM
Cancer Chemother Biol Response Modif; 2002; 20():169-96. PubMed ID: 12703205
[TBL] [Abstract][Full Text] [Related]
24. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
[TBL] [Abstract][Full Text] [Related]
25. Current concepts in neuro-oncology: the cell cycle--a review.
Dirks PB; Rutka JT
Neurosurgery; 1997 May; 40(5):1000-13; discussion 1013-5. PubMed ID: 9149259
[TBL] [Abstract][Full Text] [Related]
26. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
Whittaker SR; Walton MI; Garrett MD; Workman P
Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
[TBL] [Abstract][Full Text] [Related]
27. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
[TBL] [Abstract][Full Text] [Related]
28. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
Klein MA
Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
[TBL] [Abstract][Full Text] [Related]
29. Perspectives on cancer therapy: cell cycle blockers and perturbators.
Dobashi Y; Takehana T; Ooi A
Curr Med Chem; 2003 Dec; 10(23):2549-58. PubMed ID: 14529470
[TBL] [Abstract][Full Text] [Related]
30. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
31. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
Senderowicz AM
Leukemia; 2001 Jan; 15(1):1-9. PubMed ID: 11243375
[TBL] [Abstract][Full Text] [Related]
32. Cell cycle molecular targets in novel anticancer drug discovery.
Buolamwini JK
Curr Pharm Des; 2000 Mar; 6(4):379-92. PubMed ID: 10788588
[TBL] [Abstract][Full Text] [Related]
33. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.
Hunter T; Pines J
Cell; 1994 Nov; 79(4):573-82. PubMed ID: 7954824
[No Abstract] [Full Text] [Related]
34. G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation.
Akiyama T; Sugiyama K; Shimizu M; Tamaoki T; Akinaga S
Jpn J Cancer Res; 1999 Dec; 90(12):1364-72. PubMed ID: 10665655
[TBL] [Abstract][Full Text] [Related]
35. Cancer therapy: targeting cell cycle regulators.
Johansson M; Persson JL
Anticancer Agents Med Chem; 2008 Oct; 8(7):723-31. PubMed ID: 18855574
[TBL] [Abstract][Full Text] [Related]
36. Anticancer therapeutic strategies based on CDK inhibitors.
Esposito L; Indovina P; Magnotti F; Conti D; Giordano A
Curr Pharm Des; 2013; 19(30):5327-32. PubMed ID: 23394082
[TBL] [Abstract][Full Text] [Related]
37. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
38. NF-kappaB and cell-cycle regulation: the cyclin connection.
Joyce D; Albanese C; Steer J; Fu M; Bouzahzah B; Pestell RG
Cytokine Growth Factor Rev; 2001 Mar; 12(1):73-90. PubMed ID: 11312120
[TBL] [Abstract][Full Text] [Related]
39. CDK inhibitors in cancer therapy: what is next?
Malumbres M; Pevarello P; Barbacid M; Bischoff JR
Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
[TBL] [Abstract][Full Text] [Related]
40. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
Collins I; Garrett MD
Curr Opin Pharmacol; 2005 Aug; 5(4):366-73. PubMed ID: 15964238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
